

Publikationsverzeichnis Prof. Dr. P. Hadji

Stand Februar 2012

I. Schriftenverzeichnis der Originalarbeiten

a. Erst-/ Seniorautor

gelistete Zeitschriften (JCR)

- P. **Hadji**, O. Hars, C. Wüster, K. Bock, U.-S. Albert, H.-G. Bohnet, G. Emons, K.-D. Schulz: Stiffness Index Identifies Patients with Osteoporotic Fracture Better than Ultrasound Velocity or Attenuation Alone. *Maturitas* 31: 221-226 (1999) IF 1.119
- P. **Hadji**, O. Hars, K. Bock, U. Albert, M.W. Beckmann, G. Emons, K.-D. Schulz: Age changes of Calcaneal ultrasonometry in healthy German women. *Calcified Tissue International* 65: 117-120 (1999) IF 1.976
- P. **Hadji**, O. Hars, M. Schüler, K. Bock, C. Wüster, G. Emons, K.-D. Schulz: Assessment by quantitative ultrasonometry of the effect of hormone replacement therapy on bone mass. *American Journal of Obstetrics and Gynecology* 182: 529-534 (2000) IF 2.519
- P. **Hadji**, O. Hars, G. Sturm, T. Bauer, G. Emons, K.-D. Schulz: The influence of long-term non-suppressive Levothyroxine treatment on ultrasonometry of bone in women. *European Journal of Endocrinology* 142, 5: 445-450 (2000) IF 2.103
- P. **Hadji**, O. Hars, K. Görke, G. Emons, K.-D. Schulz: Quantitative Ultrasound of the Calcaneus in Postmenopausal Women with Spine and Hip Fracture. *Journal of Clinical Densitometry* 3: 233-239 (2000) IF 1.523
- P. **Hadji**, O. Hars, K. Bock, G. Sturm, T. Bauer, G. Emons, K.-D. Schulz: The influence of menopause and body mass index on serum leptin concentrations. *European Journal of Endocrinology* 143: 55-60 (2000) IF 2.103
- P. **Hadji**, K. Körke, O. Hars, T. Bauer, G. Emons, K.-D. Schulz: The influence of hormone replacement therapy on serum Leptin levels in postmenopausal women. *Maturitas* 37: 105-111 (2000) IF 1.402
- P. **Hadji**, M. Kalder, J. Backhus, O. Hars, M. Gottschalk, K.-D. Schulz: Age-Associated Changes in Bone Ultrasonometry of the Os Calcis. Expanded Data in Healthy German Women. *J Clinical Densitometry* 5, No. 3: 297-303 (2002) IF 1.523
- P. **Hadji**, V. Ziller, M. Kalder, M. Gottschalk, L. Hellmeyer, K.-D. Schulz: Influence of pregnancy and breast-feeding on quantitative ultrasonometry of bone in postmenopausal women. *Climacteric* 5: 277-285 (2002) IF 1.932
- P. **Hadji**, K. Bock, M. Gottschalk, O. Hars, J. Backhus, G. Emons, K.-D. Schulz: The Influence of Serum Leptin Concentrations on Bone Mass Assessed by Quantitative Ultrasound in Pre- and Postmenopausal Women. *Maturitas* 44: 141-148 (2003) IF 2.068
- L. Hellmeyer, V. Ziller, G. Anderer, A. Ossendorf, S. Schmidt, P. **Hadji**: Biochemical Markers of Bone Turnover during Pregnancy: A Longitudinal Study. *Exp Clin Endocrinol Diabetis* 114: 506-510 (2006) IF 1.356
- L. Hellmeyer, A. Ossendorf, V. Ziller, I. Tekesin, S. Schmidt, P. **Hadji**: Quantitative ultrasonometry of the phalanges during pregnancy: A longitudinal study. *Climacteric* 9: 446-451 (2006) IF 2.163
- P. **Hadji**, M. Gottschalk, M. Kalder, V. Ziller, C. Jackisch, U. Wagner: Bone mass and the risk of breast cancer. The influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg Breast Cancer and Osteoporosis Trial (MABOT). *Maturitas* 56: 312-321 (2007) IF 2.068

- L. Hellmeyer, V. Ziller, S. Schmidt, P. **Hadji**: The use of i.v. Bisphosphonate in pregnancy-associated osteoporosis – a case study. *Experimental and Clinical Endocrinology & Diabetes* 115: 139-142 (2007) IF 1.356
- P. **Hadji**: Intravenous administration: international perspectives. *Bone* 41, Issue 5 : 44 (2007) IF 4.089
- P. **Hadji**, C.L. Benhamou, V. Devas, D. Masanauskaitė, E. Barrett-Connor: Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: results of BALTO II. *Joint Bone Spine* 75: 303-310 (2008) IF 1.398
- V. Ziller, M. Kalder, W. Holzhauer, U. Albert, U. Wagner, P. **Hadji**: Adherence to endocrine therapy in postmenopausal women with breast cancer. *Annals of Oncology* 20(3):431-6 (2009) IF 5.178
- P. **Hadji**, M. Ziller, D.G. Kieback, W. Dornoff, H.W. Tessen, T. Menschick, J. Kuck, F. Melchert, A. Hasenburg: Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub-study. *Annals Oncology* 20(7):1203-9 (2009) IF 5.178
- P. **Hadji**, M. Ziller, D.G. Kieback, W. Dornoff, H.W. Tesse, J. Kuck, A. Hasenburg: The effect of exemestane or tamoxifen on markers of bone turnover: Results of a sub-study of the German TEAM trial. *Breast* 18(3):159-64 (2009) IF 1.677
- P. **Hadji**, M. Ziller, C. Maskow, U. Albert, M. Kalder: The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. *Eur J Cancer* 45:3205-3212 (2009) IF 4.475
- V. Ziller, S.P. Zimmermann, M. Kalder, M. Ziller, B. Seker-Pektas, L. Hellmeyer, P. **Hadji**: Adherence and persistence in patients with severe osteoporosis treated with teriparatide. *CMRO* 26 (3): 675-681 (2010) IF 2.866
- P. **Hadji**, M. Ziller, U.S. Albert, M. Kalder: Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. *Br J Cancer* 102:645-650 (2010) IF 4.846
- P. **Hadji**, D. Gamerding, W. Spieler, P.H. Kann, H. Loeffler, K. Articus, R. Moericke: Rapid onset and sustained efficacy (ROSE) study: Results of a randomized, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with osteoporosis. *Osteoporosis International* (2011) Epub IF 4.997
- P. **Hadji**, L. Asmar, J. van Nes, T. Menschik, A. Hasenburg et al.: The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: A meta-analysis of the US, German, Netherlands and Belgium sub-studies. *Journal of Cancer Res. Clin. Oncology* (2011) Epub IF 2.261
- M. Kalder, C. Jäger, B. Seker-Pektas, K. Dinas, . Kyvernitis, P. **Hadji**: Breast cancer and bone mineral density: The Marburg Breast Cancer and Osteoporosis Trial (MABOT II). *Climacteric* (2011) Epub IF 2.240
- P. **Hadji**, M.S. Aapro, J.-J. Body, N. Bundred, A. Brufsky, R.E. Coleman, M. Gnant et al.: Management of Aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: Practical Guidance for prevention and treatment. *Ann Oncology* (2011) Epub IF 5.647
- J. Bryce, M. Bauer, P. **Hadji**: Aromatase inhibitor-associated bone loss in patients with breast cancer: A case report. *Eur J Oncol Nursing* Epub IF 1.126
- V. Ziller, K. Wetzlar, I. Kyvernitis, B. Seker-Pektas, P. **Hadji**: Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. *Climacteric* (2010) Epub IF 2.240

- P. **Hadji**, V. Claus, T. Seinle, M. Intorcia, V. Ziller, K. Kostev: GRAND: the German retrospective cohort analysis on non-adherence and associated risk of fractures in osteoporotic women treated with oral bisphosphonates. *Osteoporosis Int'l* (2011) Epub IF 4.997
- P. **Hadji**, V. Ziller, D. Gamedinger, W. Spieler, K. Articus, M. Baier, R. Moericke, P.H. Kann: Rapid onset and sustained efficacy (ROSE) study of zoledronic acid and alendronate in postmenopausal women with low bone mass: quality of life, compliance and therapy preference. *Osteoporosis Int'l* (2011) IF 4.997
- P. **Hadji**, J.R. Zanchetta, L. Russo, C.P. Recknor, K.G. Saag et al.: Effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. *Osteoporosis International* (2011) IF 4.997
- P. **Hadji**, D.G. Kieback, T. Menschik, J. Tams, A. Hasenburg, M. Ziller: Correlation of treatment-emergent adverse events and clinical response to endocrine therapy: a retrospective analysis of a German sub-study of TEAM. *Ann Oncology* (2012) IF 5.178
- P. **Hadji**, J. Biskup, J. Bökhoff, M. Bonn, L. Rovati: Evaluation of efficacy, tolerability and effects on symptoms of androgenization of a generic oral contraceptive containing CMA 2mg/ethinylestradiol 0.03 mg. *Contraception* (2012) Epub

b. Co-Autor

gelistete Zeitschriften (JCR)

- C. Wüster, P. **Hadji**: Use of Quantitative Ultrasound Densitometry (QUS) in male osteoporosis. *The Aging Male* 2, 4: 228-239 (1999) IF 0.234
- U.-S. Albert, V. Duda, P. **Hadji**, K. Goerke, F. Hild, K. Bock, A. Ramaswamy, K.-D. Schulz: Imprint Cytology of Core Needle Biopsy Specimens of Breast Lesions – a Fast Approach to Detect Malignancies: A Comparison of Cytology and Histopathological Analysis of 173 Cases. *Acta Cytologica* 44, 1:57-62 (2000) IF 1.319
- F. Schütz, P. Heilmann, P. **Hadji**, R. Ziegler, C. Wüster: No advantage of the new combined octreotide – GHRH test over established GH – stimulation tests in the diagnosis of growth hormone deficiency (GHD) in adults. *Clinical Endocrinology* 19; 53 (6): 667-674 (2000) IF 2.992
- K. Bock, V.F. Duda, P. **Hadji**, J. Iwinska-Zelder, A. Ramaswamy, S. Schmidt, K.-D. Schulz: Sonographische Variabilität laktierender Adenome am Beispiel von 4 langzeitüberwachten Frauen. *Ultraschall in Med* 22: 176-181 (2001) IF1.183
- K. Bock, J. Iwinska-Zelder, V.F. Duda, C. Bonwetsch, G. Rode, P. **Hadji**, K.-J. Klose, K.-D. Schulz: Anwendbarkeit des Breast Imaging Reporting and Data System (BI-RADS) auf die klinische Mammographie des Mannes. *Röfo* 173: 1019-1024 (2001) IF 1.454
- H. Seeger, P. **Hadji**, A.O. Mueck: Endogenous estradiol metabolites stimulate the in vitro proliferation of human osteoblastic cells. *J Clin Pharmacol Therapeutics* 41: 148-152 (2003) IF 1.157
- H. Maalouf, P. **Hadji**: Age-associated changes in quantitative ultrasonometry (QUS) of the os calcis in Lebanese women – assessment of a Lebanese reference population. *J Musculoskel Neuron Interact* 3: 232-239 (2003) IF 0.234
- K. Bock, P. **Hadji**, K.-D. Schulz, U. Wagner, V. Duda: DD: Poland-Syndrom – Unilateral betonte Thelarche. *Ultraschall in Med* 24: 377-382 (2003) IF 1.473
- L. Hellmeyer, P. **Hadji**, V. Ziller, U. Wagner, S. Schmidt: Osteoporose in der Schwangerschaft. *Geburtsh Frauenheilk*, 64: 38-45 (2004) IF 0.726

- M. Gambacciani, D. de Aloysio, D. Elia, M.J. van der Mooren, P. **Hadji**, C. Wüster: Quantitative ultrasound (QUS) of bone in the management of postmenopausal women. *Maturitas* 47: 139-149 (2004) IF 2.045
- K. Bock, V. Duda, P. **Hadji**, E. Sax, K. Klose, U. Wagner: Differenzialdiagnose der adoleszenten Anisomastie. *RoeFo* 177: S41-S376, PO 101 (2005) IF 1.450
- K. Bock, V. Duda, P. **Hadji**, A. Ramaswamy, R. Schulz-Wendtland, K.-J. Klose, U. Wagner: Pathologic breast conditions in childhood and adolescence. *J Ultrasound Med* 24: 1347-1354 (2005) IF 1.010
- F. Fischer, M. Kuhl, U. Feek, M. Romingers, M.L. Schipper, P. **Hadji**, U. Wagner, C. Jackisch: Bone metastases in vulvar cancer: a rare metastatic pattern. *Int J Gynecol Cancer* 15: 1173-1176 (2005) IF 1.150
- K. Bock, P. **Hadji**, A. Ramaswamy, S. Schmidt, V. Duda: Rationale for a diagnostic chain in gestational breast tumor diagnosis. *Archives of Gynecology and Obstetrics* 273: 337-345 (2006) IF 1.078
- P.E. Goss, P. **Hadji**, M. Subar, P. Abreu, T. Thomsen, J. Banke-Bochita: Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. *Breast Cancer Res* 9 (4): R52 (2007) IF 4.160
- S. Boonen, F. Marin, G.B. Obermayer-Pietsch, M.E. Simoes, C. Barker, G. Lyritis, E.V. Glass, P. **Hadji**, G. Lyritis, H. Oertel, T. Nickelsen, E.V. McCloskey: Effects of prior antiresorptive therapy on the bone mineral density. Response to two years of teriparatide treatment in postmenopausal women with osteoporosis: Final results from the Eurofors trial. *J Clin Endocrinol Metab* 93: 852-860 (2008) IF 5.799
- A. Brufsky, N. Bundred, R. Coleman, R. Lambert-Falls, R. Mena, P. **Hadji** et al.: Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. *Oncologist* 13 (5): 503-514 (2008) IF 5.206
- B. Obermayer-Pietsch, F. Marin, E.V. McCloskey, P. **Hadji**, J. Farrerons, S. Boonen, M. Audran, C. Barker, A. Anastasilakis, W. Fraser, T. Nickelsen for the EUROFORs: Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. *JBMR* 23: 1591-1600 (2008) IF 6.635
- D.B. Hans, J.A. Shepherd, E.N. Schwarz, P. **Hadji** et al.: Peripheral Dual-Energy X-ray absorptiometry in the management of osteoporosis: The 2007 ISCD official positions. *J Clin Densitom* 11: 188-206 (2008) IF 2.277
- J.P. Brown, R. L. Prince, C. Deal, R.R. Recker, D.P. Kiel, L.H. de Gregorio, P. **Hadji** et al.: Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. *JBMR* 24: 153-161 (2009) IF 6.004
- R. Eastell, T. Nickelsen, F. Marin, C. Barker, P. **Hadji**, J. Farrerons, M. Audran, S. Boonen et al.: Sequential treatment of severe postmenopausal osteoporosis after teriparatide: Final results of the randomized, controlled European Study of Forsteo (EUROFORs). *JBMR* 24, 4: 726-736 (2009) IF 6.635
- A. Frassoldati, A. Brufsky, N. Bundred, R. Lambert-Falls, P. **Hadji**, N. Schenk, O. Pajja, R. Mena, R. Coleman: The effect of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO-FAST trials. *The Breast* 18; Suppl 1: 51-52 (2009) IF 1.677

- D.G. Kieback, N. Harbeck, P. **Hadji**, G. Weyer, T. Menschik, A. Hasenbrug: Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound sub-study. *J Gyn Oncol* (2010) Epub IF 3.733
- J.A. Cauley, D. Black, S. Boonen, S.R. Cummings, P. Mesenbrink, L. Palermo, Z. Man, P. **Hadji**, I.R. Reid on behalf of the Horizon Pivotal Fracture Group: Once-Yearly Zoledronic Acid and days of disability, bed rest and back pain: randomized controlled HORIZON Pivotal fracture trial. *JBMR* (2011) Epub IF 6.635
- C.J.H. van de Velde, D. Rea, C. Seynaeve, H. Putter, A. Hasenbrug, J.M. Vannetzel, R. Paridaens, C. Markopoulos, E.T.M. Hille, D.G. Kieback, L. Asmar, J. Smeets, J. Nortier, P. **Hadji**, J. Bartlett, S. Jones: Adjuvant Tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. *Lancet* 377 (2011) Epub IF 30.76
- W. v.d. Water, C. Markopoulos, C. v.d. Velde, C. Seynaeve, P. **Hadji** et al.: Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. *JAMA* 6 590-597 (2012)

II. Verzeichnis weiterer Veröffentlichungen

1. Übersichtsarbeiten

a. Erst-/Seniorautor

- J. Stevenson, M. Birkhäuser, M. Brincat, P. **Hadji**: HRT, osteoporosis and regulatory authorities. *Quis custodiet ipsos custodes?* *Human Reproduction* 21 (7): 1668-1671 (2006) IF 3.365
- R.E. Coleman, W.W. Bolten, M. Landsdown, C. Jackisch, D. Merkel, N. Maass, P. **Hadji** on behalf of the Arthralgia Working Group: Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. *Cancer Treatment Reviews* 34: 275-282 (2008) IF 4.370
- P. **Hadji**: Menopausal symptoms and adjuvant therapy-associated adverse events. *Endocrine-Related Cancer* 15:73-90 (2008) IF 4.736
- P. **Hadji**, N. Bundred: Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. *Semin Oncol* 34 (6 S4): S4-10 (2007) IF 3.064
- P. **Hadji**, A. Brufsky, M. Tubiana-Hulin, T. Guise, J.J. Body, M.S. Aapro: Practical guidance for the management of aromatase inhibitor-associated bone loss. *Ann Oncol* 19 (8): 1407-1416 (2008) IF 5.178
- P. **Hadji**: Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. *Critical Reviews in Oncology/Hematology* 69: 73-82 (2008) IF 4.490
- R. Chlebowski, J. Cuzick, D. Amakye, Ingo Bauerfeind, A. Buzdar, P. **Hadji**: Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. *The Breast* 18: S1-11 (2009) IF 1.677
- T. Fehm, D. Felsenberg, M. Krimmel, E. Solomayer, D. Wallwiener, P. **Hadji**: Consensus paper Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment. *The Breast* (accepted July 2009) IF 1.677
- P. **Hadji**, Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. *Critical Reviews in Oncology/Hematology* (2009) doi:10.1016/j.critrevonc.2009.02.001 IF 4.490
- P. **Hadji**: Dosing of Zoledronic acid throughout the treatment continuum in patients with breast cancer. *Climacteric* (2011) Epub IF 2.240

- P. **Hadji**, M. Gnant, M. Aapro, A. Lipton, R. Coleman: Dosing of zoledronic acid throughout the treatment continuum in patients with breast cancer. *Critical Rev Oncol/Hematol* (2010) IF 4.490
- P. **Hadji**: Clinical Considerations for the use of antiresorptive agents in the treatment of metastatic bone disease. *Critical Rev Oncology/Hematology* (2010) accepted 16.7.2010 IF 4.490
- M. Gnant, P. **Hadji**: Prevention of bone metastases and management of bone health in early breast cancer. *Breast Cancer Research* (2010) Epub IF 5.326
- P. **Hadji**: Managing bone health with zoledronic acid: Review of randomized clinical study results. *Climacteric* (2011) Epub IF 2.240

b. Co-Autor

- C. Wüster, P. **Hadji**: Use of Quantitative Ultrasound Densitometry (QUS) in male osteoporosis. *Calcified Tissue* 69: 225-228 (2001) IF 2.209
- H. Burger, D. Archer, D. Barlow, P. **Hadji** et al.: Practical recommendations for hormone replacement therapy in the peri- and postmenopause. *Climacteric* 7: 210-216 (2004) IF 1.932
- F. Fischer, M. Kuhl, U. Feek, M. Romingers, M.L. Schipper, P. **Hadji**, U. Wagner, C. Jackisch: Bone metastases in vulvar cancer: a rare metastatic pattern. *Int J Gynecol Cancer* 15: 1173-1176 (2005) IF 1.15
- A. Genazzani, M. Gambacciani, H. Schneider, C. Christiansen, P. **Hadji** et al.: Postmenopausal osteoporosis: therapeutic options. *International Menopause Society Expert Workshop; November 13 – 16, 2004, Pisa, Italy. Climacteric* 8: 99-109 (2005) IF 1.932
- P. Collins, G. Rosano, C. Casey, C. Daly, M. Gambacciani, P. **Hadji**, R. Kaaja et al.: Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. *Europ Heart Journal* 28: 2028-2040 (2007) IF 7.286
- M. Aapro, P.A. Abrahamsson, J.J. Body, R.E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, P. **Hadji**, W. Jonat, A. Lipton, A. Monnier, R. Rizzoli, F. Saad, B. Thürlimann: Guidance on the use of bisphosphonates in solid tumours. *Ann Oncol* 19 (3): 420-432 (2007) IF 5.178
- R.E. Coleman, T. A. Guise, A. Lipton, G.D. Roodman, P. **Hadji** et al.: Advancing treatment for metastatic bone cancer: Consensus recommendations from the second Cambridge conference. *Clin Cancer Res* 14 (20): 6387-6395 (2008) IF 6.177
- T. Rabe, M. Bettendorf, B. Friedmann-Bette, P. **Hadji**, T. Strowitzki: Einfluss von hormonellen Kontrazeptiva auf das Größenwachstum und den Knochenbau von 12-14jährigen Mädchen: Stellungnahme der DGGEFö. *J Reproduktionsmed Endokrinol* 6 (5): 2004-213 (2009)
- R.E. Coleman, T.A. Guise, A. Lipton, P. **Hadji** et al.: Metastasis and Bone Loss: Advancing Treatment and Prevention. *Consensus Recommendations from the Third Cambridge Conference. Cancer Treatment Reviews.* (2010) IF 4,790
- R.E. Coleman, L. Costa, F. Saad, R. Cook, P. **Hadji**, E. Terpos et al.: Consensus on the utility of bone markers in the malignant bone disease setting. *Critical Reviews Oncology/Hematology.* (2011) Epub IF 4.490
- T.D. Rachner, P. **Hadji**, L.C. Hofbauer: Novel therapies in benign and malignant bone diseases. *Pharmacology Therapeutics* (2012) accepted IF 8.694

3. Buchbeiträge

- „Diagnostik und Therapie der Osteoporose. Möglichkeiten und Grenzen in der gynäkologischen Praxis“ in „Die prämenopausale Menopause“, C. Keck (Hrsg.), Unimed-Verlag, Bremen 2000

- Buchkapitel in Keck, Neulen, Behre, Breckwoldt: Endokrinologie, Reproduktionsmedizin, Andrologie. Thieme-Verlag, Praxis der Frauenheilkunde Band I, 2. Auflage, Stuttgart 2002
- Buchkapitel in Hedtmann, Götte (Hrsg.): Praktische Orthopädie - Osteoporose, 41. Tagung des Berufsverbandes der Ärzte für Orthopädie e.V., Steinkopf Verlag, Darmstadt 2002
- Buchkapitel in Keck et al: Klimakterium - Menopause, Unimed-Verlag, Bremen 2002
- Buchbeitrag „Osteodensitometrie heute“ in „Lifestyle & Anti-Aging Medizin“, T. Rabe u. T. Strowitzki (Hrsg.), Rendezvousverlag, Baden-Baden 2002
- Buchbeitrag „Wirkungsmechanismen von Hormontherapien“ in „Hormontherapie des Mammakarzinoms – Revising the bookshelf“, C. Jackisch, P. Hadji, A. Rody, K. Bock, U. Wagner, Unimed-Verlag, Bremen 2003
- Buchbeitrag „Internistische Erkrankungen bei Hypophysenerkrankungen“ C. Wüster/P. Hadji in „Therapieleitfaden, Hypophysenerkrankungen“, G.K. Stalla (Hrsg), Unimed-Verlag, Bremen 2003
- Buchkapitel „Quantitative Ultrasonometry of Bone in the Management of Postmenopausal Osteoporosis“ in “Postmenopausal Osteoporosis”, Hrsg. A.R. Genazzani, Parthenon-Verlag & Martin Dunitz-Verlag, London 2006
- Buchkapitel „Prävention und Behandlung des therapieinduzierten Knochenverlustes“ – Kapitel 9A, in „Supportive Therapie von Knochenmetastasen“, 2. Auflage, Hrsg. Schmid u. Possinger, UNI-MED Verlag, Bremen 2005
- Buchkapitel „Hormontherapie im Rahmen der Prävention der postmenopausalen Osteoporose“ in „Evidenzbasierte Therapie der Osteoporose“, Hrsg. Faßbender, UNI-MED Verlag, Bremen 2006
- Buchkapitel „Raloxifen (SERM) in der Therapie der postmenopausalen Osteoporose“ in „Evidenzbasierte Therapie der Osteoporose“, Hrsg. Faßbender, UNI-MED Verlag, Bremen 2006
- Buchkapitel „Wie kann sich die primäre Osteoporose bei der Frau manifestieren?“, Hrsg. Fassbender/Pfeilschifter, Schattauer-Verlag, Stuttgart 2008
- Buchkapitel „Endokrinologie der perimenopausalen Übergangsphase, der Postmenopause und des Seniums“ (Kap. 9) in „Klinische Endokrinologie für Frauenärzte“, Hrsg. Leidenberger, Stowitzki, Ortmann, Springer Medizin Verlag, Heidelberg 2008
- Buchkapitel „Klinik der Perimenopause, der Postmenopause und des Seniums“ (Kap. 19) in „Klinische Endokrinologie für Frauenärzte“, Hrsg. Leidenberger, Stowitzki, Ortmann, Springer Medizin Verlag, Heidelberg 2008
- Buchkapitel „Tumorthherapieinduzierte Osteoporose beim Mammakarzinom“ – Kapitel 11.1. bis 11.13. in „Supportive Therapie von Knochenmetastasen“, 3. Auflage, Hrsg. Schmid u. Possinger, UNI-MED Verlag, Bremen 2010

4. Bücher

- „Osteo-Onkologie – RANKL-Inhibition beim Mammakarzinom“ M. Gnant, P. **Hadji**, (Hrsg.), Uni-Med Verlag, Bremen 2009
- Handbook of Cancer-Related Bone Disease“ R.E. Coleman P.-A. Abrahamsson, P. **Hadji** (editors), Bio Scientifica, Bristol (UK) 2010